AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 52 min read$OKLO

DeWitte Jacob sold $3.2M of OKLO (indirect holdings)

DeWitte Jacob (Co-Founder, CEO) sold 80,000 indirectly-held shares of Oklo Inc. (OKLO) at an average of $40.46 ($38.55–$41.35, $3.24M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DeWitte Jacob
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$OKLO
Bearish
medium confidence
Mentioned
$OKLO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLOBearishLow
01

Why it matters

The disclosed fact is the size, timing, and 10b5-1 nature of the insider sale. Without additional company-specific catalysts, the trading implication is mainly sentiment and positioning rather than fundamentals.

02

Market read

Traders may note the disclosed insider selling amount and timing, but the 10b5-1 structure reduces the signal strength.

03

What to watch

The article does not state whether other insiders sold/bought around the same window, nor does it provide context on total insider holdings beyond the post-transaction share count.

Relevance 5/10Novelty 3/10Timing: Filed Aug 5, transaction dated Aug 3 (post-trade disclosure).

Background

This is an SEC Form 4 insider transaction disclosure for Oklo Inc., reported by CEO/co-founder DeWitte Jacob, with sales executed across multiple trades on Aug 3.

Company-level read

Ticker impact

$OKLOBearishMedium confidence
Context

Oklo Form 4 shows CEO/co-founder DeWitte Jacob sold $3.24M of OKLO shares via a 10b5-1 plan on Aug 3.

Expected impact

Likely limited near-term impact; any effect should fade unless paired with other new catalysts.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or regulatory action in the text.

Market effects

Sector

No sector-wide read-through is provided beyond a single-company insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Oklo Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    DeWitte Jacob

    Co-founder, CEO, and 10% owner who sold shares indirectly under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 9
$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

neutronbytes.com6 min
AUG 7
$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

yahoo.com10 min
AUG 7
$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.

fxleaders.com6 min
AUG 7
$OKLOMedAI 8/10

Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance

Oklo Inc. (NYSE: OKLO) reported Q2 2026 revenue of $1.21M versus a $126,250 analyst estimate and an EPS loss of $(0.28) versus an estimated $(0.16). The company said it ended the quarter with $1.6B cash and expects 2026 operating cash flow of $120M to $150M and capex of $400M to $500M. It also advanced Aurora regulatory steps and said its Groves reactor reached first criticality.

scanx.trade7 min